Ceva acquires French vaccine manufacturer Biovac
Move will reinforce group’s strategy to find alternative solutions to use of antibiotics
Ceva Santé Animale has purchased Biovac Laboratories, a leading manufacturer of autogeneous (bacterial) vaccines, allergy treatments and reagents based in Angers, France.
Biovac, like Ceva, has experienced double-digit growth for several years as veterinarians seek alternatives to control bacterial conditions often now difficult to treat with “classic” antibiotherapy. The company has significant expertise in microbiology, allowing it to provide custom-made solutions for veterinarians and their customers.
Ceva already offers custom vaccines to leading poultry and swine producers in other parts of the world. The strategy is in line with Ceva’s stated policy of putting the veterinarian back at the center of the fight against microbial diseases. Auto vaccines are produced only after identification and diagnosis of the disease serotype by a qualified veterinarian. In cases where a “standard vaccine” will not be effective, custom vaccines can be produced and prescribed by the veterinarian in 4 to 5 weeks, creating an extremely reactive and precise service for livestock producers.
Dr. Marc Prikazsky, chairman and CEO of Ceva said: “As a veterinarian, I know how disappointing it can be to make a diagnosis and then not have the precise tool necessary to control the disease. Biovac provides an extraordinary service to the veterinarians in France. Through this partnership, we will share all our expertise in vaccine production and new technologies, so that together we can provide veterinarians in new markets with an even better service.”